Abstract
The interaction of dendritic cells (DCs) and T cells has been the cornerstone of approaches to cancer immunotherapy. Antitumoral immune responses can be elicited by delivering cancer antigens to DCs. As antigen presenting cells, these DCs activate cancer antigen specific T cells. Whereas the first part of the review discusses methods for delivery of cancer vaccines to DCs, in this part the focus is on the potential role of nanoscopic devices for molecular imaging of these immune responses. Nanoscopic devices could potentially deliver tracking molecules to DCs, enabling monitoring of DCs and/or T cell activation and tumoricidal activity during immunotherapy, using non-invasive imaging modalities such as nuclear imaging (single photon emission computed tomography (SPECT), positron emission tomography (PET)), magnetic resonance imaging (MRI) and optical imaging.
Keywords: Cancer vaccines, dendritic cells, immunomonitoring, nanotechnology, targeting, Antitumoral immune, nanoscopic devices, tomography, endoscopy, mediastinoscopy, laparoscopy
Current Drug Delivery
Title: Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Volume: 8 Issue: 3
Author(s): Ryan W. Hung, Samar Hamdy, Azita Haddadi, Zahra Ghotbi and Afsaneh Lavasanifar
Affiliation:
Keywords: Cancer vaccines, dendritic cells, immunomonitoring, nanotechnology, targeting, Antitumoral immune, nanoscopic devices, tomography, endoscopy, mediastinoscopy, laparoscopy
Abstract: The interaction of dendritic cells (DCs) and T cells has been the cornerstone of approaches to cancer immunotherapy. Antitumoral immune responses can be elicited by delivering cancer antigens to DCs. As antigen presenting cells, these DCs activate cancer antigen specific T cells. Whereas the first part of the review discusses methods for delivery of cancer vaccines to DCs, in this part the focus is on the potential role of nanoscopic devices for molecular imaging of these immune responses. Nanoscopic devices could potentially deliver tracking molecules to DCs, enabling monitoring of DCs and/or T cell activation and tumoricidal activity during immunotherapy, using non-invasive imaging modalities such as nuclear imaging (single photon emission computed tomography (SPECT), positron emission tomography (PET)), magnetic resonance imaging (MRI) and optical imaging.
Export Options
About this article
Cite this article as:
W. Hung Ryan, Hamdy Samar, Haddadi Azita, Ghotbi Zahra and Lavasanifar Afsaneh, Part II: Targeted Particles for Imaging of Anticancer Immune Responses, Current Drug Delivery 2011; 8 (3) . https://dx.doi.org/10.2174/156720111795256219
DOI https://dx.doi.org/10.2174/156720111795256219 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) Ion Channels and Epilepsy
Current Pharmaceutical Design Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Current Perspectives in the Application of Medicinal Plants Against Cancer: Novel Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Editorial (Hot Topic: Translational Medicine is Promoting Cross-talk of Interdiscipline)
Anti-Cancer Agents in Medicinal Chemistry Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry Cigarette Smoke Decreases Salivary 18 kDa Translocator Protein Binding Affinity – in Association with Oxidative Stress
Current Medicinal Chemistry Ultrasound-Mediated Cancer Therapeutics Delivery using Micelles and Liposomes: A Review
Recent Patents on Anti-Cancer Drug Discovery Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Recent Approaches and Success of Liposome-Based Nano Drug Carriers for the Treatment of Brain Tumor
Current Drug Delivery